文献速递艾滋病与性传播感染

美国南部城市Ryan White诊所HIV-1病毒血症患者使用长效卡博特韦/利匹韦林、来那卡帕韦和伊巴利珠单抗的回顾性分析

Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South.
PubMed 文献 · Clin Infect Dis · 2026-01-01

完成至少3次长效卡博特韦/利匹韦林注射的79例中,73例(92%)在注射中位1次后实现病毒抑制,提示LA-ART可在治疗障碍和疾病负担较重人群中帮助实现终结HIV流行目标。

要点

  • 病毒血症HIV感染者启动长效卡博特韦/利匹韦林方案后,92%在注射中位1次后实现病毒抑制。
  • 645次长效卡博特韦/利匹韦林注射中98%按时给药,来那卡帕韦和伊巴利珠单抗注射全部按时。
  • 2例出现伴耐药突变的病毒学失败,4例持续病毒血症但无耐药。

核心结论

  • 在 largest southern US cohort(美国南部最大队列)的病毒血症HIV感染者中,92%启动长效抗逆转录病毒治疗后实现病毒抑制,支持LA-ART作为实现终结HIV流行目标的工具。

主要发现

  • 启动时中位病毒载量4.0 log10,中位CD4+ 186 cells/μL。
  • 79例持续参与中73例(92%)在注射中位1次后实现病毒抑制(<50 c/mL),CD4+升至中位353 cells/μL。
  • 2例病毒学失败伴耐药,4例持续病毒血症无耐药(>200 c/mL 2例;50-200 c/mL 2例)。
  • 645次长效卡博特韦/利匹韦林注射中635次(98%)按时给药,来那卡帕韦43/43次和伊巴利珠单抗37/37次均按时给药。

临床怎么用

  • 对口服ART下仍病毒血症的HIV感染者,可考虑启动长效卡博特韦/利匹韦林方案,必要时联合来那卡帕韦或伊巴利珠单抗,并重视按时注射以维持病毒抑制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with HIV (PWH) with viremia despite oral antiretroviral therapy (ART) can achieve viral suppression (VS) using long-acting (LA)-ART. Scaling this approach has lagged, especially in the highest HIV burden areas. METHODS: We performed a retrospective review of PWH who initiated LA-ART (cabotegravir/rilpivirine [CAB/RPV] ± lenacapavir [LEN] ± ibalizumab [IBA]) with viremia (≥50 c/mL) at a Ryan White-funded program in the urban South between 14 April 2021 and 31 August 2024. Among PWH who received ≥3 LA-CAB/RPV injections through end of follow-up (31 December 2024), achieving VS (<50 c/mL) was assessed. RESULTS: Eighty-one PWH with viremia initiated LA-ART. Among them, 93% identified as Black, 40% were cis-/trans-women, the median (Q1-Q3) age was 38 (30-49) years, and the median income was $25K/year ($20-33K/year). The median (Q1-Q3) time since HIV diagnosis was 15.5 (8.8-20.5) years, and 46% had prior opportunistic conditions. At LA-ART initiation (56 CAB/RPV; 22 CAB ± RPV + LEN; 3 CAB ± RPV + LEN + IBA), the median (Q1-Q3) viral load was 4.0 (2.9-4.8) log10 and CD4 + 186 (62-420) cells/μL. Of 79 PWH who remained engaged, 73 (92%) achieved VS after a median (Q1-Q3) of 1 (1-2) injection, with CD4 rise to 353 (187-501) cells/μL. Otherwise, 2 had virologic failure with drug resistance; 4 had persistent viremia without resistance (>200 c/mL [n = 2]; 50-200 c/mL [n = 2]). Of 645 LA-CAB/RPV injections (500 Q4wk; 145 Q8wk), 635 (98%) were administered on-time; all LEN (43/43) and IBA (37/37) administrations occurred on-time. CONCLUSIONS: In the largest southern US cohort of PWH with viremia initiating LA-ART, 92% achieved VS despite significant barriers to care and disease burden, underscoring LA-ART as a tool to help achieve Ending the HIV Epidemic goals.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Colasanti JA, Aldredge A, Niles-Carnes LV, et al. Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. Clin Infect Dis. 2026. PMID: 40747944. doi:10.1093/cid/ciaf425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。